PTC's Sephience Launch Drives Record Revenue, Raised Guidance, and Pipeline Expansion
Sephience launch momentum PTC's PKU drug Sephience generated $151 million in Q2 2026, up 21% from Q1, with 1,647 patients on therapy. The launch is ahead of expectations, driving product revenue and supporting the raised full-year guidance.
Sephience is the main growth engine and the key reason for the raised guidance and record revenue.
Record Q2 revenue and raised guidance PTC reported record Q2 revenue of $361 million, more than doubling product revenue, and raised full-year product revenue guidance to $850–950 million. Management expects cash flow breakeven in 2026, with $2.23 billion in cash.
The earnings beat and guidance raise are the period's biggest fundamental news, directly affecting valuation.
Acquisition of ST-920 gene therapy for Fabry disease PTC agreed to acquire ST-920, a late-stage gene therapy for Fabry disease, for $111 million upfront plus milestones. The deal expands the pipeline and leverages PTC's rare disease commercial infrastructure, targeting a 2027 launch.
This is a new strategic move that adds a near-term pipeline asset and potential future revenue.
Competitive threat to Emflaza from Catalyst's Agamree Catalyst's Agamree showed comparable efficacy to PTC's Emflaza with less immunosuppression in a phase I study, potentially threatening Emflaza's market position. Emflaza contributed $25 million in Q2, a small but declining part of PTC's portfolio.
This is a real competitive risk that could pressure Emflaza sales, though it is a minor part of PTC's overall revenue.